BioStem Technologies Files Audited Financial Statements, Advancing Nasdaq Uplisting Efforts

BioStem Technologies, Inc. has filed its audited consolidated financial statements for the fiscal years ended December 31, 2024 and 2025. The company, which focuses on developing, manufacturing, and commercializing perinatal tissue allograft products, stated that this publication represents a significant step toward its goal of uplisting to the Nasdaq stock exchange. The financial statements are available for review on the OTC Markets website at https://www.otcmarkets.com.

Jason Matuszewski, Chairman and CEO of BioStem Technologies, emphasized the importance of this milestone. He noted that alongside recent appointments of a new CFO, auditor, and audit committee chair, the achievement highlights the company's efforts to establish robust financial reporting processes. Matuszewski stated that listing on Nasdaq remains a top priority, as it would increase the company's visibility, improve stock liquidity, provide a more precise market valuation, and enhance its ability to attract top talent. The company's progression toward this goal comes as it continues to advance its corporate initiatives in the competitive regenerative medicine field.

BioStem Technologies utilizes proprietary processing technologies including BioRetain®, CryoTek®, and SteriTek® to optimize the preservation of natural tissue properties for clinical use. The company's quality management system and standard operating procedures have been accredited by the American Association of Tissue Banks and are established in compliance with current Good Tissue Practices and current Good Manufacturing Processes. Its product portfolio includes the Neox®, Clarix®, VENDAJE®, and American Amnion™ lines, which are used by clinicians across various medical specialties. For additional information about the company and its products, visit https://biostemtechnologies.com.

The publication of audited financial statements represents a critical requirement for companies seeking to uplist from over-the-counter markets to major exchanges like Nasdaq. This move typically requires meeting specific financial reporting standards, corporate governance requirements, and minimum share price thresholds. For BioStem Technologies, achieving a Nasdaq listing would potentially provide greater access to institutional investors and increased analyst coverage, which could support the company's growth objectives in the expanding regenerative medicine market. The company's focus on perinatal tissue allografts places it within a specialized segment of the biomedical industry where innovation and clinical validation are key drivers of commercial success.